Valuation Neuland Laboratories Limited

Stocks

Market Closed - Bombay S.E. Other stock markets 06:00:55 2026-07-30 EDT			5-day change	1st Jan Change
19,217.00 ^INR	-2.53%		+4.28%	+26.51%

05-25	LIR Life Sciences Announces Start of Phase 1 of Transdermal Delivery Development Activities	MT
05-22	LIR Life Sciences Announces Initiation of Phase 1 Macromolecule-Enabled Transdermal Delivery Development with Neuland Laboratories	CI

Data adjusted to current consolidation scope

Fiscal Period: March	2022	2023	2024	2025	2026	2027	2028	2029
Market Cap ¹	13,171	23,087	80,588	154,946	154,121	246,552	-	-
Change	-	75.28%	249.07%	92.27%	-0.53%	59.97%	-	-
Enterprise Value (EV) ¹	13,171	23,087	80,374	153,929	153,584	249,489	248,472	245,855
Change	-	75.28%	248.14%	91.52%	-0.22%	62.44%	-0.41%	-1.05%
P/E	20.6x	14.1x	26.9x	-	42.3x	60.3x	43.7x	-
PBR	1.58x	-	6.32x	10.2x	8.27x	11.2x	9.03x	-
PEG	-	0x	0.3x	-	-	4x	1.2x	-
Capitalization / Revenue	1.38x	1.94x	5.17x	10.5x	7.62x	10.7x	8.87x	7.44x
EV / Revenue	1.38x	1.94x	5.16x	10.4x	7.59x	10.8x	8.94x	7.42x
EV / EBITDA	9.24x	8.49x	17.4x	47.6x	26.7x	38.4x	28.3x	24.2x
EV / EBIT	14.1x	-	19.9x	59.7x	31.8x	44.8x	31.5x	26.9x
EV / FCF	-35.3x	13.5x	68.4x	139x	-304x	62.1x	67.1x	-
FCF Yield	-2.83%	7.41%	1.46%	0.72%	-0.33%	1.61%	1.49%	-
Dividend per Share ²	-	10	14	12	34	13.25	18.95	42.63
Rate of return	-	0.56%	0.22%	0.1%	0.28%	0.07%	0.1%	0.22%
EPS ²	49.74	127.4	233.9	-	283.7	326.9	450.9	-
Distribution rate	-	7.85%	5.99%	-	12%	4.05%	4.2%	-
Net sales ¹	9,511	11,912	15,586	14,768	20,230	23,088	27,799	33,148
EBITDA ¹	1,426	2,718	4,626	3,233	5,745	6,492	8,774	10,178
EBIT ¹	935.8	-	4,029	2,577	4,828	5,571	7,883	9,152
Net income ¹	638.2	1,635	3,001	2,601	3,640	4,209	5,806	-
Net Debt ¹	-	-	-214.1	-1,017	-536.9	2,937	1,920	-697.1
Reference price ²	1,026.60	1,799.45	6,281.30	12,076.95	12,012.65	19,716.30	19,716.30	19,716.30
Nbr of stocks (in thousands)	12,830	12,830	12,830	12,830	12,830	12,830	-	-
Announcement Date	5/10/22	5/11/23	5/10/24	5/15/25	5/12/26	-	-	-

¹INR in Million²INR

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
NEULAND LABORATORIES LIMITED	60.32x	11.08x	39.42x	0.07%	2.64B
ELI LILLY AND COMPANY	35.93x	12.83x	26.95x	0.56%	1,079B
JOHNSON & JOHNSON	28.47x	6.51x	18.01x	2.02%	640B
ABBVIE INC.	33.14x	7.75x	15.92x	2.61%	465B
ROCHE HOLDING AG	20.04x	4.79x	11.87x	2.76%	353B
NOVARTIS AG	22.45x	5.8x	14.46x	2.76%	301B
ASTRAZENECA PLC	22.33x	4.59x	13.01x	1.91%	271B
NOVO NORDISK A/S	14.91x	5.52x	11.38x	3.36%	228B
AMGEN INC.	25.46x	6.65x	11.72x	2.6%	209B
GILEAD SCIENCES, INC.	-47.83x	5.73x	31.65x	2.48%	165B
Average	21.52x	7.13x	19.44x	2.11%	371.23B
Weighted average by Cap.	25.12x	8.06x	18.97x	1.93%